peptide research is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-30. Numbers and descriptions here follow the published literature rather than marketing material.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
=== Prostate cancer === Sarcosine has been debated as a biomarker for prostate cancer cells. Other research has suggested that sarcosine plays an active role in the progression of prostate cancer, as addition of sarcosine to prostate epithelial cells caused the emergence of a new invasive phenotype.
=== Zachery treatment === A proprietary process was created by electrical engineer and turquoise dealer James E. Zachery in the 1980s to improve the stability of medium to high-grade turquoise. The process can be applied in several ways: either through deep penetration on rough turquoise to decrease porosity, by shallow treatment of finished turquoise to enhance color, or both. The treatment can enhance color and improve the turquoise's ability to take a polish. Such treated turquoise can be distinguished in some cases from natural turquoise, without destruction, by energy-dispersive X-ray spectroscopy, which can detect its elevated potassium levels. In some instances, such as with already high-quality, low-porosity turquoise that is treated only for porosity, the treatment is undetectable.
Cell growth and proliferation are affected by G6PD. Pharmacologically ablating G6PD has been shown to overcome cross-tolerance of breast cancer cells to anthracyclines. G6PD inhibitors are under investigation to treat cancers and other conditions. In vitro cell proliferation assay indicates that G6PD inhibitors, DHEA (dehydroepiandrosterone) and ANAD (6-aminonicotinamide), effectively decrease the growth of AML cell lines. G6PD is hypomethylated at K403 in acute myeloid leukemia, SIRT2 activates G6PD to enhance NADPH production and promote leukemia cell proliferation.
Sources: en.wikipedia.org
=== Thomson Medal Award (since 1985) === 2024 Jennifer S. Brodbelt 2022 Vicki Wysocki and Lidia Gall 2020 Alison E. Ashcroft 2014 Carol V. Robinson 2009 Catherine E. Costello and Catherine. C. Fenselau
(SEM-EDS): scanning electron microscopy–energy dispersive spectroscopy is used for directly studying the surfaces of solid objects, that utilizes a beam of focused electrons of relatively low energy as an electron probe that is scanned in a regular manner over the specimen. The electron source and electromagnetic lenses that generate and focus the beam are similar to those described for the transmission electron microscope (TEM). The action of the electron beam stimulates the emission of high-energy backscattered electrons and low-energy secondary electrons from the surface of the specimen. data from this process can be used to create 3D renderings of materials. (XRD): X-ray diffraction is a phenomenon in which the atoms of a crystal, by virtue of their uniform spacing, cause an interference pattern of the waves present in an incident beam of X rays. The atomic planes of the crystal act on the X rays in exactly the same manner as does a uniformly ruled grating on a beam of light. X-ray signals can be used to map estimate the concentration of elements in the sample. Microscopic Examination offers the ability to see the damage that is invisible to the naked eye, as well as aid in identifying specific materials. The identification of fibers “may not only adduce the origin of an artifact, for example, but can also serve as a predictor of behavior and so is essential in allowing an informed decision on conservation protocol.
=== St–Sz === Frank Stahl (1929–2025), US molecular biologist known for the Meselson-Stahl experiment Donald F. Steiner (1930–2014). American biochemist at the University of Chicago, who made ground breaking discoveries in the treatment of diabetes. Member Natl. Acad. Sci. USA Joan Steitz FRS (foreign associate) (b. 1941). American biochemist at Yale University, best known for her work on RNA. Member Natl. Acad. Sci. USA. Thomas A. Steitz FRS (foreign associate) (1940–2018). American biochemist at Yale University, best known for his pioneering work on the ribosome. Nobel Prize in Chemistry, 2009. Member Natl. Acad. Sci. USA. Marjory Stephenson FRS (one of the first two women elected) (1885-1948). British biochemist and microbiologist at Cambridge University, most widely remembered for her seminal book, Bacterial Metabolism. Audrey Stevens (1932–2010). American biochemist at Oak Ridge National Laboratory, co-discoverer of RNA polymerase. Member Natl. Acad. Sci. USA. Bruce Stone (1928–2008). Australian biochemist known for work in cereal and grass polysaccharides. Foundation Professor of Biochemistry at La Trobe University (1972–1993). Lubert Stryer (1938–2024). American biophysicist at Stanford who pioneered the use of fluorescence spectroscopy, particularly Förster resonance energy transfer, to monitor the structure and dynamics of biological macromolecules. He is best known for his textbook Biochemistry. Member Natl. Acad. Sci. USA. Paul K.
The "Peacock Cave" (Pfauenhöhle in German) is also an early cave, although dated slightly later to circa 400 CE, and next located "Cave of the statues" (Cave 77), in the second rocky outcrop just outside of the central valley. It has been carbon dated to mid 4th-end 5th century CE. It is said to be "the most recognizably Indian in the whole Kizil cycle". The paintings echo the Art of Gandhara and the murals of Ajanta Caves. A rectangular vestibule, the vaulted roof of which is now collapsed, preceded the main chamber. The main chamber has a domed ceiling, an innovation first seen in early caves at Bamiyan, and in caves 83 and 84 at Kizil. Numerous statuettes of the Buddha, as well as decorated wooden benches and low display tables were discovered in the antechamber of the cave. In the center of the main chamber, there is a large podium, on which probably stood some major statuary associated with the Buddha. The architecture of the cave displays a marked advancement compared to earlier caves, but is anterior to the "central pillar" cave structure. Several paintings illustrate the life of the Buddha. Only the left wall of the main cella had remained in great part intact by the time Grünwedel visited. The top part of the wall showed four important moments of the life of the Buddha, while celestial observers stand on a balcony above: 1) the Birth of Siddharta and the first Three Steps in which the Buddha appears naked and already tall, 2) the Four Encounters outside of the palace, 3) the Seduction of Mara's daughters, who are turned into old women, and 4) the Assault of Mara.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.